Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,346 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo, intravenous Clear all
Withdrawn Phase 2 Interventional

Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite

NCT04401527
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Acute Respiratory Failure
Interventions
Sodium Nitrite, Normal Saline
Drug
Lead sponsor
Hope Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Tampa, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1 Interventional

Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme

NCT01934361
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
buparlisib, carboplatin, lomustine, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery

NCT01901588
View directory record Official record
Conditions
Strabismus, Delirium on Emergence, Pediatric Disorders
Interventions
Dexmedetomidine, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 7 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 2 Interventional

CCI-779 in Treating Patients With Prostate Cancer

NCT00012142
View directory record Official record
Conditions
Prostate Cancer
Interventions
temsirolimus
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair

NCT00528970
View directory record Official record
Conditions
Ileus
Interventions
MOA-728, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
75
States / cities
Benton, Arkansas • Colton, California • Laguna Hills, California + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

NCT02497469
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Vedolizumab, Adalimumab placebo, Adalimumab, Vedolizumab placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
77
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects

NCT01449188
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
ondansetron, moxifloxacin, saline
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Results available

A Study of LY3113593 in Participants With Chronic Kidney Disease

NCT02604160
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
LY3113593, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Orlando, Florida • Indianapolis, Indiana • Shreveport, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue

NCT04141696
View directory record Official record
Conditions
Fatigue
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 4 Interventional

Premedication for Less Invasive Surfactant Administration Study (PRELISA)

NCT05065424
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
IV Atropine and Fentanyl Premedication Arm, IV Normal Saline Placebo Arm
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
0 Hours to 72 Hours
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 3, 2026, 10:49 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients

NCT07810946
View directory record Official record
Conditions
Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
Interventions
Sodium Acetate, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

NCT01064388
View directory record Official record
Conditions
Healthy
Interventions
AZD9742, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
23 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women

NCT01742091
View directory record Official record
Conditions
Healthy
Interventions
LY2541546 - SC, LY2541546 - IV, Placebo - SC, Placebo - IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Daytona Beach, Florida • Honolulu, Hawaii • Evansville, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain

NCT07053774
View directory record Official record
Conditions
Pain, Acute
Interventions
Intravenous oxytocin, Intravenous placebo, Intranasal oxytocin, Intranasal placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients

NCT04605978
View directory record Official record
Conditions
Primary Sjögren's Syndrome
Interventions
S95011 concentrate for solution for infusion, Placebo concentrate for solution for infusion
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Lakewood, Colorado • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers

NCT01014650
View directory record Official record
Conditions
Healthy
Interventions
GLYX-13, IV normal saline
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

Analgesic Efficacy of Repeated Doses of Intravenous (IV) Acetaminophen in Post-operative Pediatric Spine Fusion Patients

NCT01394718
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Intravenous Acetaminophen, Placebo
Drug · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 18 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects

NCT00700076
View directory record Official record
Conditions
Healthy
Interventions
Ketamine and Org 25935, Placebo and Ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke

NCT02730455
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
18
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 2 Interventional Results available

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

NCT04551898
View directory record Official record
Conditions
Covid19
Interventions
BGB-DXP593, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
DeLand, Florida • Hollywood, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 3, 2026, 10:49 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis

NCT02038049
View directory record Official record
Conditions
Relapse Remitting Multiple Sclerosis
Interventions
VAY736, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Long Beach, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants

NCT03870555
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-954, TAK-954 Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 3, 2026, 10:49 PM EDT
Terminated Phase 2 Interventional Results available

Study of BIIB092 in Participants With Progressive Supranuclear Palsy

NCT03068468
View directory record Official record
Conditions
Supranuclear Palsy, Progressive
Interventions
BIIB092, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
41 Years to 86 Years
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 3, 2026, 10:49 PM EDT
Withdrawn Phase 1 Interventional

IVIG in Acute Ischemic Stroke: A Pilot Study

NCT01628055
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Privigen, Normal Saline
Biological · Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
45 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 3, 2026, 10:49 PM EDT